Valuation: Tsubota Laboratory Incorporated

Market Cap 6.81B 43.38M 37.83M 35.72M 32.44M 60.77M 4.16B 61.03M 428M 165M 2.12B 163M 159M P/E 2025
49.7x
P/E 2026 -9.95x
Enterprise Value 5.91B 37.64M 32.82M 30.99M 28.14M 52.73M 3.61B 52.95M 371M 143M 1.84B 141M 138M EV / Sales 2025
6.38x
EV / Sales 2026 33.4x
Free-Float
28.38%
Yield 2025 *
-
Yield 2026 -
08-12 Tsubota Laboratory Incorporated Reports Earnings Results for the First Quarter Ended June 30, 2026 CI
06-17 Tsubota Laboratory Incorporated announced that it has received ¥4.129362 million in funding from Cantor Fitzgerald Europe CI
06-01 Tsubota Laboratory Incorporated announced that it expects to receive ¥4.129362 million in funding from Cantor Fitzgerald Europe CI
06-01 Tsubota Laboratory Incorporated signed a letter of intent to acquire MediProduce, Inc. from Eri Kubota for ¥150 million. CI
05-15 Tsubota Laboratory Incorporated Reports Earnings Results for the Full Year Ended March 31, 2026 CI
05-15 Tsubota Laboratory Incorporated Provides Non Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2027 CI
02-13 Tsubota Laboratory Incorporated Provides Non Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2026 CI
02-13 Tsubota Laboratory Incorporated Reports Earnings Results for the Nine Months Ended December 31, 2025 CI
12/05/25 Tsubota Laboratory Incorporated Provides Earnings Guidance for the Fiscal Year Ending March 31, 2026 CI
17/02/25 Tsubota Laboratory Incorporated Revises Earnings Guidance for the Fiscal Year Ending March 31, 2025 CI
20/11/24 Tsubota Laboratory Incorporated Provides Earnings Guidance for the Fiscal Year Ending March 31, 2025 CI
19/12/22 Certain Common Stock of Tsubota Laboratory Incorporated are subject to a Lock-Up Agreement Ending on 19-DEC-2022. CI
20/09/22 Certain Common Stock of Tsubota Laboratory Incorporated are subject to a Lock-Up Agreement Ending on 20-SEP-2022. CI
1 day+1.54%
1 week+2.72%
Current month-11.41%
1 month-5.38%
3 months+15.79%
6 months-30.71%
Current year-22.35%
1 week 252
Extreme 252
271
1 month 251
Extreme 251
305
Current year 210
Extreme 210
478
1 year 210
Extreme 210
478
3 years 210
Extreme 210
625
5 years 210
Extreme 210
1,447
10 years 210
Extreme 210
1,447
Manager TitleAgeSince
President 71 01/02/2019
Chief Administrative Officer - -
Chief Tech/Sci/R&D Officer 65 01/01/2025
Director TitleAgeSince
Director/Board Member 71 01/02/2019
Director/Board Member 70 01/06/2020
Director/Board Member 55 01/06/2023
Date Insider Type Main position Quantity % Market Cap. Importance
15/11/24 Others

Founder

63,000 0.2465%
15/11/24 Others

Founder

420,000 1.6434%
Change 5-day change 1-year change 3-year change Capi.($)
+1.54%+2.72%-24.36%-49.62% 43.38M
+0.11%+2.71%+0.33%+28.59% 46.28B
-1.12%+1.78%+40.07%+27.26% 43.85B
-3.04%-6.29%+322.27%+517.36% 40.93B
-0.74%+1.25%+2.32%+67.94% 39.9B
-0.50%+0.67%+11.79%+40.51% 29.5B
-0.46%+4.22%+21.99%+124.21% 17.09B
-0.97%-10.17% - - 15.55B
-0.57%+8.12%+22.15%+38.93% 15.22B
-3.14%+31.91%-10.60% - 14.05B
Average -0.74%+3.66%+42.89%+99.40% 26.24B
Weighted average by Cap. -1.02%+1.87%+64.68%+130.20%

Financials

2025 2026
Net sales 1.36B 8.64M 7.54M 7.12M 6.46M 12.11M 830M 12.16M 85.26M 32.9M 422M 32.47M 31.75M 200M 1.27M 1.11M 1.05M 953K 1.78M 122M 1.79M 12.57M 4.85M 62.16M 4.79M 4.68M
Net income 205M 1.31M 1.14M 1.08M 976K 1.83M 125M 1.84M 12.88M 4.97M 63.71M 4.91M 4.8M -761M -4.85M -4.23M -3.99M -3.62M -6.79M -465M -6.82M -47.81M -18.45M -237M -18.21M -17.81M
Net Debt -1.45B -9.22M -8.04M -7.6M -6.9M -12.92M -885M -12.98M -90.98M -35.11M -450M -34.65M -33.88M -901M -5.74M -5.01M -4.73M -4.29M -8.04M -551M -8.07M -56.61M -21.85M -280M -21.56M -21.08M
Logo Tsubota Laboratory Incorporated
Tsubota Laboratory Inc is a Japan-based company mainly engaged in the research and development of new treatments for myopia, dry eye, and presbyopia. The Company operates with a B2B business model. The model generates revenue from lump-sum payments under joint research and development agreements and licensing agreements with partner companies, milestone payments, and royalties under post-commercialization (post-launch) loyalty agreements and creates new value by investing the profits in the new research. The Company is also engaged in the research and development of products for adults that treat depression and dementia, improve sleep and increase concentration.
Employees
-
Date Price Change Volume
18/09/26 ¥264.00 +1.54% 15,000
17/09/26 ¥260.00 +1.56% 24,100
16/09/26 ¥256.00 -4.48% 59,300
15/09/26 ¥268.00 +4.28% 51,700
14/09/26 ¥257.00 0.00% 35,700
  1. Stock Market
  2. Stocks
  3. 4890 Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!